Which of the following is a FDA-approved labeled indication for cyclobenzaprine hydrochloride?

A. Avelox is the proprietary brand name for moxifloxacin, a fourth-generation fluoroquinolone. While it shares the same pharmacological class as ciprofloxacin, its chemical structure contains a methoxy group for improved gram-positive activity. It is not the brand name for ciprofloxacin.

B. Augmentin is a combination of amoxicillin and clavulanate potassium, representing a beta-lactam antibiotic and a beta-lactamase inhibitor. It targets bacterial cell wall synthesis rather than DNA gyrase. This medication is chemically and mechanistically distinct from the fluoroquinolone class.

C. Cipro is the brand name for ciprofloxacin, a second-generation fluoroquinolone. It functions by inhibiting bacterial DNA gyrase and topoisomerase 4, which are essential for DNA replication. This mechanism provides potent bactericidal activity against a wide range of aerobic pathogens.

D. Levaquin is the brand name for levofloxacin, the S-enantiomer of the racemic mixture ofloxacin. It is a third-generation fluoroquinolone with a broader spectrum of activity against respiratory pathogens than ciprofloxacin. It is a separate pharmaceutical product from ciprofloxacin hydrochloride.

A. Prevention of exercise-induced bronchospasm is a labeled indication for albuterol sulfate. It is administered prophylactically to stabilize mast cells and prevent airway constriction. This ensures patent airways during physical exertion in patients with hyperreactive airway disease.

B. Allergic rhinitis involves inflammatory responses in the nasal mucosa rather than the lower respiratory tract. Albuterol is a sympathomimetic bronchodilator and lacks the antihistaminic or anti-inflammatory properties required for this condition. It provides no therapeutic benefit for nasal congestion.

C. Relief of bronchospasm in patients with reversible obstructive airway disease is the primary indication. Albuterol acts as a selective beta-2 adrenergic agonist to increase intracellular cyclic adenosine monophosphate. This results in the relaxation of bronchial smooth muscle and rapid bronchodilation.

D. Rhinorrhea associated with the common cold is caused by viral-induced nasal inflammation and increased glandular secretion. Albuterol does not possess the anticholinergic or vasoconstrictive effects needed to reduce nasal discharge. Its pharmacological activity is limited to the beta receptors of the bronchi.